



## Company Announcement

### Nykode Therapeutics - Invitation to Capital Markets Day in Oslo on September 27, 2023

- *Management to host a Capital Markets Day in Oslo, Norway on September 27 from 2:00 p.m.-4:30 p.m. CET.*
- *Highlights to be covered include recent developments within our pipeline of innovative cancer vaccines, with a spotlight on the differentiating factors of our Nykode technology platform and our leading assets, VB10.16 (wholly owned) and VB10.NEO (in collaboration with Genentech).*
- *The event is a live event with physical attendance only. The presentation slides may be accessed from the Company's website.*

Oslo, Norway, September 25, 2023 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, invites to a Capital Markets Day for analyst and investors in Oslo on September 27, 2023 from 2:00 p.m.-4:30 p.m. CET. The event will be hosted as a live event with physical attendance only. The presentation slides may be accessed from the Company's website.

The Capital Markets Day will feature Nykode's Executive Management Team who will provide an update on the development and future potential of Nykode's business, as well as a deep dive into our strategic vision. During this event, we will present recent developments within our pipeline of innovative therapeutic vaccines with a spotlight on the differentiating factors of our Nykode technology platform, an update on our activities within autoimmunity and our leading oncology assets, VB10.16 (wholly owned) and VB10.NEO (in collaboration with Genentech, a member of the Roche Group).

For a comprehensive overview of our agenda and additional details, please refer to the full schedule attached hereto.

Attendance requires registration as spaces are limited. To register for the physical event, please send an email to ABG Sundal Collier, e-mail: [invitations@abgsc.no](mailto:invitations@abgsc.no) by Tuesday September 26, 2023.

#### **Event details**

Date and time: September 27, 2023 from 2:00 p.m.-4:30 p.m. CET

Location: ABG Sundal Collier, Ruseløkkveien 26, 8<sup>th</sup> floor, 0251 Oslo

Presentation material: <https://nykode.com/investors/financial-reports-and-presentations>



The archived webcast of last week's Capital Markets Day in New York, including the presentation by Dr. Bradley Monk, VP and Member of the Board of Directors of the GOG-Foundation, may be accessed on the following link:

[https://event.webcasts.com/starthere.jsp?ei=1633969&tp\\_key=dc0959d03d](https://event.webcasts.com/starthere.jsp?ei=1633969&tp_key=dc0959d03d)

### **About Nykode Therapeutics**

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on treatment of cancer and autoimmune diseases. Nykode's modular vaccine technology specifically targets antigens to APC, which have been shown to induce broad, strong and long-lasting antigen specific immune responses which correlates with clinical responses in cancer.

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of cervical cancer; and VB10.NEO, an individualized cancer neoantigen vaccine, which is exclusively out-licensed to Genentech, a member of the Roche Group.

The Company's partnerships include Genentech within oncology and a multi-target collaboration with Regeneron within oncology and infectious diseases.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics may be found at <http://www.nykode.com>.

### **Forward-looking statements for Nykode Therapeutics**

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

### **Contact for Nykode Therapeutics ASA:**

Alexandra Deschner, Head of IR  
Nykode Therapeutics ASA  
[IR@nykode.com](mailto:IR@nykode.com)

### **Nykode Therapeutics ASA**

Oslo Science Park  
Gautstadalléen 21  
N-0349 Oslo, Norway